Available Until 10/22/2022

Best Practices for the Safe and Cost-Effective Management of Controlled Substances

NOTE: If you attended the live CE activity that was held on October 22, 2020 AND received CE credit (i.e. a pharmacist or Pharmacy Technician CE statement of credit with ACPE UAN 0221-9999-20-507-L05-P/T), you are NOT allowed to also receive credit for this home-study on-demand web activity.

Activity Description

This session will provide guidance to assess an organization’s medication-use processes for vulnerabilities and identify strategies that may improve the capacity to prevent or detect diversion. Speakers will discuss known diversion cases, vulnerabilities in the medication use process, literature, case studies, guidelines, as well as their personal experiences. They will review a recent study that quantified the drug and workforce waste cost and discuss the use of healthcare technologies as a mechanism to reduce the opportunity for diversion. Thorough system-based strategies that can broaden an organization’s response to diversion beyond that of individual accountability will be reviewed.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify practices that support medication safety and eliminate risk for drug diversion.
  • Discuss interventions to minimize diversion of controlled substances.
  • Recognize essential components of a diversion stewardship program.
  • Recall quantifiable cost data associated with opioid waste.


Introduction and Overview
Christina Michalek BSc Pharm, RPh, FASHP, Medication Safety Specialist, ISMP

Best Practices for the Safe and Cost-Effective Management of Controlled Substances
Christina Michalek BSc Pharm, RPh, FASHP, Medication Safety Specialist, ISMP

What's In Your Tool Kit? Identifying the Best Instruments for Drug Diversion Prevention
Deborah Wagner, PharmD, Clinical Professor, Pharmacy, College of Pharmacy; Clinical Professor, Anesthesiology, Medical School, University of Michigan

The Cost of Opioid Disposal: Results of a Continuous Observation Workflow Time Study
John Hertig, PharmD, MS, CPPS, Associate Professor, Butler University College of Pharmacy and Health Sciences


It is the policy of ProCE, Inc. to ensure balance, independence, objectivity and scientific rigor in all of its continuing education activities. Faculty must disclose to participants any significant financial interest or affiliation with companies that manufacture or market products discussed during their presentation. John Hertig has received grant funding from Fresenius Kabi, USA for investigator-initiated research. Christina Michalek does not have any relevant commercial and/or financial relationships to disclose. Deborah Wagner has served as an Advisory Board member for AcelRx, Heron, and Merck. Conflicts identified were resolved with a peer review process.

CE Accreditation

Release Date: 10-22-2020
Expiration Date: 10-22-2022

Pharmacists and Pharmacy Technicians

This CE activity is jointly provided by ProCE, Inc. and the Institute for Safe Medication Practices (ISMP). ProCE, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-20-507-H05-P/T has been assigned to this knowledge-based home-study CE activity. This activity is approved for 1.0 contact hour (0.1 CEU) in states that recognize ACPE providers. This CE activity is provided at no cost to participants. Statements of completion will be issued online at www.ProCE.com upon completion of the evaluation and post-test with a score of 70% or higher. Proof of completion will be posted in NABP CPE Monitor profiles. No partial credit will be given.


This CE activity is supported by an educational grant from Fresenius Kabi.


The material presented in this CE activity does not reflect the views of ProCE, LLC or the commercial sponsor. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.